Vaccine-associated-like Fibrosarcoma at the Site of a Deep Nonabsorbable Suture in a Cat

Buracco, Paolo; Martano, Marina; Morello, Emanuela; Ratto, Alessandra

doi:10.1053/tvjl.2001.0617

Cited by 61 publications

(67 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FISS may also develop after microchip implantation [14, 15] or as a reaction to non-absorbable surgical stitches [16]. FISS treatment is challenging because the local tumour recurrence rate ranges from 14 to 69% [17–20].…”

Section: Introductionmentioning

confidence: 99%

Current knowledge on feline injection-site sarcoma treatment

2017

View full text Add to dashboard Cite

Feline injection-site sarcomas (FISS) are malignant skin tumours of mesenchymal origin, the treatment of which is a challenge for veterinary surgeons. The role of surgery, radiotherapy and chemotherapy in FISS treatment has been studied, and a correlation between “clean” surgical margins and disease-free survival has been shown. In addition, clean surgical margins are one of the most important factors for achieving a low recurrence rate. The most effective method of FISS treatment includes combining radical surgery with pre- or postoperative radiotherapy. Chemotherapy may be used as a palliative method of treatment or may be considered an adjunctive therapy for surgery and radiotherapy. In cats with FISS without metastasis, the use of immunostimulant treatment with Oncept IL-2, intended as a complementary immunotherapy in association with surgery and brachytherapy, may also be considered to reduce the risk of relapse and increase the time to relapse. Additionally, this review focuses on recent advances in FISS treatment, including the use of novel compounds, such as doxorubicin conjugated to glutathione-stabilized gold nanoparticles, liposomal doxorubicin or tyrosine kinase inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Current knowledge on feline injection-site sarcoma treatment

2017

View full text Add to dashboard Cite

show abstract

“…2–4 Other agents, such as FVRCP±C, long-acting penicillin, methyl prednisolone, and suture material, have also been implicated. 5,6 …”

mentioning

confidence: 99%

Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006)

Shaw¹,

Kent²,

Gordon³

et al. 2009

javma

View full text Add to dashboard Cite

Objective To evaluate changes in characteristics of feline injection-site sarcomas (ISSs) from 1990 through 2006. Design Retrospective case series. Animals 392 cats with a histologic diagnosis of soft tissue sarcoma, osteosarcoma, or chondrosarcoma at potential injection sites. Procedures Classification and anatomic location of tumors and signalment of affected cats were compared between ISSs diagnosed before and after publication of the Vaccine Associated Feline Sarcoma Task Force vaccination recommendations in 1996. Results From before to after publication of the vaccination recommendations, proportions of ISSs significantly decreased in the interscapular (53.4% to 39.5%) and right and left thoracic (10.2% to 3.6% and 9.1% to 1.3%, respectively) regions. On the other hand, proportions of ISSs significantly increased in the right thoracic limb (1.1% to 9.5%) and the combined regions of the right pelvic limb with right lateral aspect of the abdomen (12.5% to 25.0%) and the left pelvic limb with left lateral aspect of the abdomen (11.4% to 13.8%). Patterns of tumor classification and signalment did not change. Conclusions and Clinical Relevance Despite publication of the vaccination recommendations, a high proportion of tumors still developed in the interscapular region. There was also an increase in lateral abdominal ISSs, which are more difficult to treat and are likely attributable to aberrant placement of injections intended for the pelvic limbs. Veterinarians are complying with vaccination recommendations to some extent, but they need to focus on administering vaccines as distally as possible on a limb to allow for complete surgical margins if amputation of a limb is required.

show abstract

“…Furthermore, there have so far been only a few reports about tumors in the uterine remnant of spayed female cats. Chronic local inflammation [4] and biomaterials such as nonabsorbable sutures [1] and implants [11] have been associated with the development of neoplasms in animals. In addition, chronic inflammation is regarded as one of the contributors of the SCC development in animals [12].…”

mentioning

confidence: 99%

A Spayed Female Cat with Squamous Cell Carcinoma in the Uterine Remnant

Hayashi

Tanaka

Tajima

et al. 2013

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. A 7-year-old spayed female domestic short-haired cat presented with dysuria and hematuria that had been unresponsive to medical therapy. Imaging tests such as ultrasonography, urethrocystography and computed tomography revealed a pelvic mass compressing the urethra. Based on histological examination of the mass following surgical resection, the cat was diagnosed squamous cell carcinoma (SCC) derived from the uterine remnant. After surgery, dysuria was resolved, but on instead, urine and fecal incontinence were observed. Then, about four months after surgery, recurrence of the mass and the symptoms was observed. Consequently, the cat was ultimately euthanized. This is the first report of SCC arising from the uterine remnant in a spayed female cat.

show abstract

Vaccine-associated-like Fibrosarcoma at the Site of a Deep Nonabsorbable Suture in a Cat

Cited by 61 publications

References 9 publications

Current knowledge on feline injection-site sarcoma treatment

Current knowledge on feline injection-site sarcoma treatment

Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006)

A Spayed Female Cat with Squamous Cell Carcinoma in the Uterine Remnant

Contact Info

Product

Resources

About